Rebirth of the God-level Xueba

More than 30 compounds used in animal experiments were synthesized step by step by Yang Rui.

Naturally, Yang Rui is also clear about the fate of these compounds.

In the final analysis, Yang Rui only needs one or two compounds in the end, no more than four at most, and the remaining compounds must be eliminated.

If you want to speed up, the best way is to let the compounds that should be eliminated be eliminated earlier.

The reason why the screening of active substances is getting slower and slower is naturally because the remaining compounds are getting safer and those compounds that are obviously unsafe, such as those with acute toxicity, have been brushed out in the initial few tests .

But in the next test, those unsafe compounds will eventually be eliminated, it's just a matter of time.

The problem is that Yang Rui doesn't want to wait that long.

Some tests will not be carried out until a long time later, and some are not even needed in the 1980s, but only in the 1990s.

But as a new drug developer, considering the situation ten years from now, it is completely normal. Ten years later, the new drug may not be on the market yet, and even the marketed drug may be withdrawn.

For example, a large number of drugs that were withdrawn in the 1990s were metabolized by mixed-function oxidases, which is not a problem in itself. However, patients often do not take one drug, but use multiple drugs in combination. The results are these Drugs metabolized by mixed functional oxidases are very likely to have cross-reactions, and such consequences are either not tested in animal experiments, or are also the last tests.

Because drug cross-reactivity is not the focus of animal experiments.

But from the perspective of whether a drug is successful or not, drug cross-reactions cannot escape.

Similarly, there are issues of genotoxicity, metabolites, pharmacokinetic characteristics, and even whether the raw materials are easy to obtain and whether the synthesis cost is reasonable and low.

These issues are not considered by ordinary people, but must be considered by pharmaceutical companies. For example, cold medicines after 10 years will definitely not consider products made of raw materials. Some raw materials that need to be closely monitored have such problems.

If you think about it, you can understand that if you buy a box of cold medicine and you have to check your ID card and limit the quantity, you can imagine its sales. Putting it in European and American countries is equivalent to turning non-prescription drugs into prescription drugs. , Pharmaceutical companies cannot be careless.

all in all,

All work in pharmaceutical companies is done with caution.

Whether a drug can become a clinical candidate compound after the end of animal experiments means whether it will cost 20 million to 200 million US dollars for pharmaceutical companies and wait four to five years for clinical research.

Such an amount and time are enough for two countries to engage in a local low-intensity war, and how can pharmaceutical companies be careless.

What Yang Rui needs to do is to eliminate the compounds that are destined to be eliminated as soon as possible, so that he can concentrate his time and energy on a few compounds, and then make detailed tests and analysis.

In the end, if these few compounds can meet the requirements of clinical candidate compounds, even if Yang Rui cannot personally promote them to market, pharmaceutical companies will actively do so.

The only trouble is that this kind of elimination requires Yang Rui to spend more time participating, not the other way around.

Naturally, this takes some precious time.

However, Yang Rui also felt that he needed such an experience. Desferiprone was what he wanted to do, not what Huarui needed. But one day, Huarui Laboratories still need to make their own medicines if they want to grow stronger. By that time, Yang Rui hoped that he would be a manager with pharmaceutical experience, rather than a rookie layman with great ambition and little talent.

Yang Rui occupied two compartments in the main laboratory and started the design of animal experiments.

Wei Zhenxue and Wang Xiaoyun were still in charge of the animal experiments. Yang Rui only made requests and looked at the results of the experiments, and did not directly participate.

After all, animal experiments are not always the same, even if the 3r principle is adopted, some experiments are still uncomfortable.

As a graduate student in the Department of Biology, Yang Rui has over a hundred rats under his command, but that doesn't mean he likes the job.

On the other hand, Yang Rui did not need to do such things as feeding compounds, observing and measuring the results, and finally killing the animals.

Yang Rui is busy enough designing experiments.

In order to get approved by the FDA or possibly by the Drug Administration of a European country, Yang Rui must first make a detailed experiment record, including the preamble and follow-up questions, that is, how he thought, how he did it, and what was the result.

More specifically, it is why you think this way, why you do it, what you use to do it, and the meaning of the result.

This complex process can protect the public to the greatest extent, and also restricts the progress of scientific research to the greatest extent.

However, although Yang Rui was busy enough, his progress caught Wei Zhenxue and Wang Xiaoyun by surprise.

In just two days, the two couldn't bear it any longer. When Yang Rui checked, he found that they hadn't even completed one-third of the tasks.

"The reaction time of the mice is not determined by us." Wang Xiaoyun explained helplessly, she was still busy writing the experiment report, and they had much more to write than Yang Rui.

Wei Zhenxue was so tired that he couldn't turn his head, so he said: "I haven't slept all day and night, boss, please add an assistant."

Yang Rui, who has been working for 110 hours, was shocked to see Wei Zhenxue like this, and asked Wang Xiaoyun, "You really haven't slept all day and all night?"

"I fell asleep yesterday, and Lao Tu helped me a bit." Wang Xiaoyun was a little embarrassed.

"Where's Grace?"

Wang Xiaoyun hesitated for a moment, and said, "She said she doesn't accept your order."

"why?"

"Ruan Ming probably means this." Wang Xiaoyun said: "Grace is continuing to follow the regular steps little by little."

Yang Rui pondered and asked: "What about you, do you think my experimental design is correct?"

"We have already screened out a compound. From the results, the experimental design can be used." Wang Xiaoyun didn't need to flatter Yang Rui, she said it very truthfully.

Yang Rui nodded slightly, and said: "Then continue with the current state... Is it okay not to add people?"

"We must add people, at least the people stop the equipment, so that we can speed up the screening."

This sentence moved Yang Rui. The instruments in the laboratory are limited, but it is still feasible to use them at different times.

"I'll help you find two more people." Yang Rui was unwilling to increase the lab's staff too quickly. The cost was on the one hand, and the resources were limited on the other hand. The busyness of each lab in Huarui Lab was second to none. .

After some deployment, the number of compounds decreased rapidly.

It is only the drug cross-reaction that is usually not done, and three compounds were screened out in one go. If this method is not used, these three compounds may cost the experimenter hundreds of hours and tens of thousands of dollars. was eliminated.

Within a few days, the number of candidate compounds dropped to an astonishing eight, and Grace couldn't help but come to learn from it.

...

... ()